BEND, Ore.--(BUSINESS WIRE)--EVIO Inc. (“EVIO” or the “Company”), (OTCQB: EVIO), a leading North American provider of cannabis testing and scientific research for the regulated cannabis industry, is excited to announce EVIO Biosciences launches the release of the first Genomics Testing program for Pathogen Identification in Cannabis. The EVIO Biosciences division launched in May led by EVIO’s Chief Science Officer, Dr. Anthony Smith.
EVIO is proud to offer next generation DNA sequencing services for pathogen surveillance in cannabis grow operations. Next generation sequencing services (NGSS) genetically identifies nearly all the microbial constituents in a particular sample of plant tissue, soil or water. This service can help producers identify plant pathogens contributing to loss of yield or quality in your grow facility. NGSS can also be used to identify workplace human pathogens to keep your workers safe. Perhaps more important than pathogen ID, NGSS is a powerful tool for establishing an understanding of beneficial microbial biome constituents of your soil and cannabis plants. Knowing the constituents of the microbial communities in your grow operations can be the key to unlocking the effectiveness of your soil and nutrient strategies.
Our NGSS application performs iterative sequence analysis of DNA that we isolate and prepare from environmental and plant tissue samples in your operation. The samples we collect contain hundreds or thousands of diverse microorganisms. NGSS is based on sequence-based identification of 16S ribosomal RNA genes. These genes encode an RNA molecule that are similarly conserved in nearly all living cells. In a NGSS run, sections of this gene and neighboring genetic regions are targeted to identify most present DNA sequences to the genus of species level. This information helps determine the presence and relative abundance of all microbial community constituents in the sample.
Through cooperative sampling of roots, leaves, and stem tissues, we can help to identify which beneficial and plant pathogens are present, identify the source of pathogens, and how manage their populations. We help to sample your healthy or diseased plant tissues, take these backs to the lab, extract and sequence the DNA in your samples. We interpret and report the genomic information and put together a plan to help you move forward and into the future.
Dr. Anthony Smith said, "We have achieved the goal of leveraging NGSS technology to directly improve quality and yield in Cannabis cultivation ops. It’s a part of our mission, to bring progressive technology applications into the cannabis sector, and this technology has direct applicability to other markets such as food safety, agriculture and water testing."
Dr. Anthony Smith received his PhD from Oregon State University in Molecular & Cellular Biology with an emphasis on biochemistry, metabolism and nutrition. He brings over 15 years of natural product research, quality assurance, product development, GMP manufacturing, FDA & regulatory experience and analytical expertise to EVIO.
About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company’s EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply. The Company’s EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.
For more information, visit www.eviolabs.com.
Safe Harbor Statement
Any statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com.